Centre Hospitalier Henri Laborit
Poitiers, 86000, France
Location status: Recruiting
NCT Number: NCT05865652
The management of schizophrenia is a major public health issue, due to its particularly disabling psychotic symptoms and their onset at an early age, typically in adolescents or young adults.
The physiopathological hypothesis of an anomaly relating to the renewal of cell membranes and energy metabolism in schizophrenia was proposed as early as the 1930s. This is based on anomalies at certain times in the development of the balance between phosphomonesters, precursors of membrane phospholipids, and phosphodiesters, catabolites of membrane phospholipids. Alterations of these different balances sign neurodevelopmental disorders, and can be objectified by specific techniques such as phosphorus-31 magnetic resonance spectroscopy (SMR-31P). This is used in particular to characterize the energy metabolism of the brain and allows in vivo quantification of phosphorus metabolites.
The application of SMR-31P techniques to assess the metabolism of membrane phospholipids and cellular energy metabolism in subjects at high risk of psychotic transition could make it possible to objectify a difference between subjects subsequently suffering from a psychotic transition compared to those who do not suffer from it. Alterations in the metabolism of membrane phospholipids could thus represent a biomarker of psychotic transition. Secondarily, this approach would make it possible to provide elements as to the validity as a diagnosis of this category, which is very heterogeneous in its future.
Among the Ultra High Risk (UHR) group, subjects with a psychotic transition (UHR-T) are compared to subjects without this transition (UHR-NT) during the two years of follow-up.
The UHR group is compared to the control group.
At T0, UHR patients and healthy volunteers will perform brain MRI with Phosphorus 31 magnetic resonance spectroscopy.
UHR patients will then be reviewed:
* at T+1 year for a clinical assessment medical interview to assess the patient's functioning and the appearance of symptoms; * at T+2 years for the realization of a follow-up interview with passing of the scales CAARMS (Comprehensive Assessment of At Risk Mental State) and SOFAS (scale of evaluation of the social and professional functioning) in order to determine if the subject belongs to the UHR-T or UHR-NT group.
Interested in participating?
Request Info15 year–25 year
All sexes
Interventional
Not applicable
Poitiers, 86000, France
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for the UHR group:
Inclusion criteria
for the Control group:
Exclusion criteria
for the UHR group:
The relative contraindications are to be considered, namely: previous surgical interventions, medically implanted device, tattoo or permanent make-up.
Exclusion criteria
for the control group:
The relative contraindications are to be considered, namely: previous surgical interventions, medically implanted device, tattoo or permanent make-up.
Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Time frame: 2 years
Levels measurements of inorganic phosphate.
Time frame: 2 years
Levels measurements of phosphocreatine.
Time frame: 2 years
Levels measurements of Gamma ATP.
Time frame: 2 years
Levels measurements of Alpha ATP.
Time frame: 2 years
Levels measurements of beta ATP.
Time frame: 2 years
Levels measurements of intracellular pH.
Time frame: 2 years
Levels measurements of phosphodiester.
Time frame: 2 years
Levels measurements of phosphomonoester.
Time frame: 2 years
Levels measurements of inorganic phosphate.
Time frame: 2 years
Levels measurements of phosphocreatine.
Time frame: 2 years
Levels measurements of Gamma ATP.
Time frame: 2 years
Levels measurements of Alpha ATP.
Time frame: 2 years
Levels measurements of beta ATP.
Time frame: 2 years
Levels measurements of intracellular pH.
Time frame: 2 years
Levels measurements of phosphodiester.
Time frame: 2 years
Levels measurements of phosphomonoester.
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Henri Laborit
Other
Evaluation of Membrane Phospholipid Metabolism and Cellular Energy Metabolism in Subjects at High Risk of Psychotic Transition
Acronym: MR7T-UHR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.